Unknown

Dataset Information

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.


ABSTRACT:

Background

New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells.

Methods

We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) to assess safety, pharmacokinetic profile, and efficacy. In the dose-escalation phase, 56 patients received active treatment in one of eight dose groups that ranged from 150 to 1200 mg per day. In an expansion cohort, 60 additional patients were treated with a weekly stepwise ramp-up in doses as high as 400 mg per day.

Results

The majority of the study

SUBMITTER: Roberts AW 

PROVIDER: S-EPMC7107002 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature